構造心臓デバイス市場の2032年までの予測：製品別、手技別、年齢層別、適応症別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の構造心臓デバイス市場は2025年に87億3,000万米ドルを占め、予測期間中のCAGRは11.3％で成長し、2032年までには184億7,000万米ドルに達する見込みです。

構造心臓デバイスと呼ばれる医療用インプラントや器具は、壁、弁、内部開口部などの壊れたり欠陥のある心臓コンポーネントを交換または修正するために作られます。弁狭窄、逆流、心房中隔欠損、左心房付属器閉鎖不全などの症状を治療する場合、これらの器具は不可欠です。構造心臓デバイスは開心術よりも患者の回復が早く、合併症も少ないため、経カテーテル手技のような低侵襲手技の進歩により、その使用は劇的に増加しています。さらに、人口の高齢化と心血管系疾患の罹患率の上昇により、世界のあらゆる医療システムでこれらの機器の必要性が高まっています。

世界保健機関（WHO）によると、心血管疾患（CVD）は世界の死因の第1位で、毎年推定1,790万人の命を奪っています。これらの疾患には、冠動脈性心疾患、脳血管疾患、リウマチ性心疾患など、さまざまな心臓・血管障害が含まれます。

心血管疾患の有病率の増加

心臓弁膜症、中隔欠損、左心房付属器の異常などの心臓の構造的な疾患は、心血管疾患（CVDs）の世界の負担の増大の主な原因となっています。世界保健機関（WHO）によると、年間約1,800万人がCVDが原因で死亡しています。経カテーテル弁、オクルーダー、環状形成リングのような構造心臓デバイスの需要は、大動脈弁狭窄症や僧帽弁閉鎖不全症のような、外科手術やカテーテルベースの介入を必要とする病態の有病率の上昇によって促進されています。これらの病態は時間の経過とともに悪化することが多いため、罹患率や死亡率を低下させるためには、器具を用いた迅速な介入が極めて重要です。

高価な機器と手技

構造的心臓インターベンション、特にTAVRやTMVRのような経カテーテル技術を用いたインターベンションには、高額な手技費用と機器費用が伴います。入院費、画像診断、術後ケアに加え、経カテーテル弁1個にかかる高額な費用（3万米ドルに達することもある）が加わると、患者とヘルスケアシステムへの全体的な負担は相当なものになります。中低所得国（LMICs）では、保険が適用されず、ヘルスケア資金が不十分であるため、こうした救命処置へのアクセスはさらに制限されています。さらに、医療技術機関の費用対効果評価は、先進国においてさえ、特に無症状または中間リスクの患者に対する幅広い採用を妨げたり、延期したりする可能性があります。

カスタマイズされた新進気鋭の機器の創出

安全性、堅牢性、使いやすさを向上させた次世代の構造心臓デバイスの開発には大きな可能性があります。合併症を減少させ、手技管理を向上させるため、各社はより小型で、完全に取り出し可能で、再配置可能な弁の作成に注力しています。デジタル画像と3Dプリンティングの開発により、カスタマイズされた患者専用機器も、特に解剖学的課題を抱える症例において、適合性と機能を最大限に高めることができます。さらに、これらの機器は、スマートセンサーやデジタルヘルス技術を組み込むことで、リアルタイムのモニタリングを提供し、処置後のケアを強化し、病院の再入院率を低下させる可能性があります。

高い価格圧力と市場競争

Edwards Lifesciences、Medtronic、Abbott、Boston Scientificなどの大手企業は、競争の激しい構造心臓市場において、常に革新的な製品を開発し、ポートフォリオを多様化しています。市場競争は創造性を刺激しますが、特に参入企業が増えるにつれて価格圧力も高まります。病院の入札に基づく調達慣行、消費者の経済的解決策への欲求の高まり、医療システムや保険会社との協議の結果、コストが低下することも多いです。さらに、特に規模の経済に制約のある新興企業や中小企業にとっては、利益率がこの価格感応度によって悪影響を受ける可能性があります。

COVID-19の影響：

COVID-19パンデミックは、主に選択的手術の延期と病院リソースのクリティカルケアへの再配分により、構造心臓デバイス市場に短期的に大きな影響を与えました。パンデミックの最盛期には、経カテーテル弁置換術や修復術など多くの構造的心臓治療が延期された結果、手術件数と機器売上が一時的に減少しました。さらに、医療機器の生産と流通も、グローバルサプライチェーンの混乱によって影響を受けました。その一方で、パンデミックはデジタルヘルス技術の採用を早め、入院期間の短縮や低侵襲手技の重要性を再認識させました。

予測期間中、大動脈弁狭窄症分野が最大となる見込み

大動脈弁狭窄症分野は、経カテーテル大動脈弁置換術（TAVR）の普及と高齢者人口におけるその高い有病率により、予測期間中に最大の市場シェアを占めると予想されます。外科的弁置換術よりも侵襲性の低い選択肢であるTAVRは、特に手術リスクが高い、または中程度の患者に対して人気を博しています。手術成績の改善、低リスク患者への適応拡大、機器設計の進歩により、採用率は大幅に上昇しています。さらに、この分野は、認知度の向上、償還支援、臨床的成功率により、心臓構造インターベンションの展望における成長の主要なドライバーとなっています。

外来手術センター（ASCs）分野は予測期間中に最も高いCAGRが見込まれる

予測期間中、外来手術センター（ASCs）分野が最も高い成長率を示すと予測されます。ASCには、処置費用の削減、入院期間の短縮、患者の回転の早さ、院内感染の可能性の低下など、いくつかの利点があります。これらのセンターでは、手技の安全性の向上とデバイスの小型化により、多くの心臓構造インターベンション、特に経カテーテル手技を実施できるようになりました。投資の拡大、有利な償還制度改革、便利な治療環境に対する患者の選好などが、ASCの爆発的な成長に寄与し、構造的心臓治療分野における重要な成長エンジンとしての地位を確立しています。

最大のシェアを占める地域

予測期間中、北米地域は高齢者人口の増加、心血管疾患の高い有病率、洗練されたヘルスケアインフラを背景に、最大の市場シェアを占めると予想されます。大手市場プレイヤーの存在と確立された償還政策に加え、この地域は研究開発への大規模投資の恩恵を受けています。さらに、市場の力強い成長は、低侵襲手技に対する意識の高まりや、経カテーテル的大動脈弁置換術（TAVR）や左心房付属器閉鎖術のような最先端技術の使用の増加の結果でもあります。

CAGRが最も高い地域：

予測期間中、アジア太平洋が最も高いCAGRを示すと予測されます。人口の高齢化、ヘルスケアへのアクセスの容易さ、心血管疾患に対する意識の高まりなど、数多くの要因がこの急速な拡大の原因となっています。構造心臓デバイス市場はインドがリードしています。さらに、左心房付属器閉鎖術（LAAC）や経カテーテル的大動脈弁置換術（TAVR）のような低侵襲手技の使用が、この地域の市場拡大を牽引しています。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の構造心臓デバイス市場：製品別

• 心臓弁デバイス
  • 外科用心臓弁
  • 経カテーテル心臓弁
• 環状形成リング
• 閉塞器具・デリバリーシステム
• アクセサリー

第6章 世界の構造心臓デバイス市場：手技別

• 交換手順
  • 外科的大動脈弁置換術（SAVR）
  • 経カテーテル大動脈弁置換術（TAVR）
  • 経カテーテル僧帽弁置換術（TMVR）
  • その他の交換手順
• 修理手順
  • 左心耳閉鎖術（LAAC）
  • 経カテーテル僧帽弁修復術（TMVr）
  • 経カテーテル三尖弁修復術（TTVr）
  • 弁形成術
  • その他の修理手順

第7章 世界の構造心臓デバイス市場：年齢層別

• 小児
• 大人

第8章 世界の構造心臓デバイス市場：適応症別

• 心房中隔欠損症（ASD）
• 心室中隔欠損症（VSD）
• 卵円孔開存症（PFO）
• 大動脈弁狭窄症
• その他の適応症

第9章 世界の構造心臓デバイス市場：エンドユーザー別

• 病院
• 外来手術センター
• 心臓カテーテル検査室
• その他のエンドユーザー

第10章 世界の構造心臓デバイス市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第11章 主な発展

• 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第12章 企業プロファイリング

• Boston Scientific Corporation
• Artivion, Inc.
• Medtronic Plc
• Edwards Lifesciences Corporation
• Abbott Laboratories
• JenaValve Technology, Inc.
• LivaNova PLC
• Meril Lifesciences Pvt. Ltd
• LifeTech Scientific Corporation
• Terumo Corporation
• Numed Inc
• Atricure, Inc
• Cook Group Incorporated
• Lepu Medical Inc
• Braile Biomedica Inc

List of Tables

• Table 1 Global Structural Heart Devices Market Outlook, By Region (2024-2032) ($MN)
• Table 2 Global Structural Heart Devices Market Outlook, By Product (2024-2032) ($MN)
• Table 3 Global Structural Heart Devices Market Outlook, By Heart Valve Devices (2024-2032) ($MN)
• Table 4 Global Structural Heart Devices Market Outlook, By Surgical Heart Valves (2024-2032) ($MN)
• Table 5 Global Structural Heart Devices Market Outlook, By Transcatheter Heart Valves (2024-2032) ($MN)
• Table 6 Global Structural Heart Devices Market Outlook, By Annuloplasty Rings (2024-2032) ($MN)
• Table 7 Global Structural Heart Devices Market Outlook, By Occluders and Delivery Systems (2024-2032) ($MN)
• Table 8 Global Structural Heart Devices Market Outlook, By Accessories (2024-2032) ($MN)
• Table 9 Global Structural Heart Devices Market Outlook, By Procedure (2024-2032) ($MN)
• Table 10 Global Structural Heart Devices Market Outlook, By Replacement Procedure (2024-2032) ($MN)
• Table 11 Global Structural Heart Devices Market Outlook, By Surgical Aortic Valve Replacement (SAVR) (2024-2032) ($MN)
• Table 12 Global Structural Heart Devices Market Outlook, By Transcatheter Aortic Valve Replacement (TAVR) (2024-2032) ($MN)
• Table 13 Global Structural Heart Devices Market Outlook, By Transcatheter Mitral Valve Replacement (TMVR) (2024-2032) ($MN)
• Table 14 Global Structural Heart Devices Market Outlook, By Other Replacement Procedures (2024-2032) ($MN)
• Table 15 Global Structural Heart Devices Market Outlook, By Repair Procedure (2024-2032) ($MN)
• Table 16 Global Structural Heart Devices Market Outlook, By Left Atrial Appendage Closure (LAAC) (2024-2032) ($MN)
• Table 17 Global Structural Heart Devices Market Outlook, By Transcatheter Mitral Valve Repair (TMVr) (2024-2032) ($MN)
• Table 18 Global Structural Heart Devices Market Outlook, By Transcatheter Tricuspid Valve Repair (TTVr) (2024-2032) ($MN)
• Table 19 Global Structural Heart Devices Market Outlook, By Valvuloplasty (2024-2032) ($MN)
• Table 20 Global Structural Heart Devices Market Outlook, By Other Repair Procedures (2024-2032) ($MN)
• Table 21 Global Structural Heart Devices Market Outlook, By Age Group (2024-2032) ($MN)
• Table 22 Global Structural Heart Devices Market Outlook, By Pediatric (2024-2032) ($MN)
• Table 23 Global Structural Heart Devices Market Outlook, By Adults (2024-2032) ($MN)
• Table 24 Global Structural Heart Devices Market Outlook, By Indication (2024-2032) ($MN)
• Table 25 Global Structural Heart Devices Market Outlook, By Atrial Septal Defect (ASD) (2024-2032) ($MN)
• Table 26 Global Structural Heart Devices Market Outlook, By Ventricular Septal Defect (VSD) (2024-2032) ($MN)
• Table 27 Global Structural Heart Devices Market Outlook, By Patent Foramen Ovale (PFO) (2024-2032) ($MN)
• Table 28 Global Structural Heart Devices Market Outlook, By Aortic Valve Stenosis (2024-2032) ($MN)
• Table 29 Global Structural Heart Devices Market Outlook, By Other Indications (2024-2032) ($MN)
• Table 30 Global Structural Heart Devices Market Outlook, By End User (2024-2032) ($MN)
• Table 31 Global Structural Heart Devices Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 32 Global Structural Heart Devices Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
• Table 33 Global Structural Heart Devices Market Outlook, By Cardiac Catheterization Labs (2024-2032) ($MN)
• Table 34 Global Structural Heart Devices Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Structural Heart Devices Market is accounted for $8.73 billion in 2025 and is expected to reach $18.47 billion by 2032 growing at a CAGR of 11.3% during the forecast period. Medical implants or instruments called structural heart devices are made to replace or fix broken or flawed cardiac components, such as walls, valves, or internal openings. When it comes to treating conditions like valve stenosis, regurgitation, atrial septal defects, and left atrial appendage closure, these devices are essential. Because structural heart devices offer patients a quicker recovery and fewer complications than open heart surgery, their use has increased dramatically due to advancements in minimally invasive procedures like transcatheter techniques. Moreover, the need for these devices is increasing in all global healthcare systems due to the aging population and the rising incidence of cardiovascular diseases.

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally, claiming an estimated 17.9 million lives each year. These diseases encompass a range of heart and blood vessel disorders, including coronary heart disease, cerebrovascular disease, and rheumatic heart disease.

Market Dynamics:

Driver:

Increasing cardiovascular disease prevalence

Structural heart conditions like valvular heart disease, septal defects, and abnormalities of the left atrial appendage are major contributors to the growing global burden of cardiovascular diseases (CVDs). Almost 18 million deaths annually are attributed to CVDs, according to the World Health Organization. Demand for structural heart devices like transcatheter valves, occluders, and annuloplasty rings is fueled by the rising prevalence of conditions like aortic stenosis and mitral valve regurgitation, which call for surgical or catheter-based intervention. Timely device-based intervention is crucial in lowering morbidity and mortality because these conditions frequently worsen over time.

Restraint:

Expensive equipment and procedures

High procedural and device costs are linked to structural heart interventions, particularly those that use transcatheter techniques like TAVR or TMVR. When hospital expenses, imaging, and post-operative care are added to the high cost of a single transcatheter valve-which can reach $30,000-the overall burden on patients and healthcare systems is substantial. Access to these life-saving procedures is further limited in low- and middle-income countries (LMICs) by a lack of insurance coverage and inadequate healthcare funding. Additionally, health technology agencies' cost-effectiveness evaluations can impede or postpone broad adoption, even in developed countries, especially for patients who are asymptomatic or at intermediate risk.

Opportunity:

Creation of customized and up-and-coming equipment

The development of next-generation structural heart devices that provide enhanced safety, robustness, and usability has enormous potential. In order to reduce complications and increase procedural control, companies are concentrating on creating smaller, fully retrievable, and repositionable valves. owing to developments in digital imaging and 3D printing, customized and patient-specific devices can also maximize fit and function, particularly in cases that present anatomical challenges. Furthermore, these devices may offer real-time monitoring, enhance post-procedure care and lower hospital readmission rates by incorporating smart sensors and digital health technologies.

Threat:

High levels of price pressure and market competition

Major companies like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific are constantly innovating and diversifying their portfolios in the fiercely competitive structural heart market. Although competition encourages creativity, it also increases pricing pressure, particularly as more businesses enter the market. Hospitals' tender-based procurement practices, consumers' increasing desire for economical solutions, and discussions with health systems and insurers frequently result in lower costs. Moreover, profit margins may be adversely affected by this price sensitivity, especially for startups or smaller businesses with constrained economies of scale.

Covid-19 Impact:

The COVID-19 pandemic had a significant short-term impact on the Structural Heart Devices Market, primarily due to the postponement of elective procedures and the reallocation of hospital resources toward critical care. Procedure volumes and device sales temporarily decreased as a result of the postponement of numerous structural heart interventions, such as transcatheter valve replacements and repairs, during the height of pandemic waves. Additionally, the production and distribution of medical devices were also impacted by disruptions in the global supply chain. On the other hand, the pandemic also hastened the adoption of digital health technologies and reaffirmed the significance of shorter hospital stays and minimally invasive procedures, which ultimately favor structural heart interventions.

The aortic valve stenosis segment is expected to be the largest during the forecast period

The aortic valve stenosis segment is expected to account for the largest market share during the forecast period, due to the widespread use of Transcatheter Aortic Valve Replacement (TAVR) procedures and their high prevalence in the elderly population. A less invasive option to surgical valve replacement, TAVR has gained popularity, especially for patients with high or intermediate surgical risk. Adoption rates have been greatly increased by improvements in procedure outcomes, expanded indications for lower-risk patients, and device design advancements. Furthermore, this segment is a major driver of growth in the structural heart intervention landscape due to rising awareness, reimbursement support, and clinical success rates.

The ambulatory surgical centers (ASCs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the ambulatory surgical centers (ASCs) segment is predicted to witness the highest growth rate. because of the increasing trend toward outpatient care and minimally invasive procedures. ASCs have several benefits, including lower procedure costs, shorter hospital stays, quicker patient turnover, and a lower chance of hospital-acquired infections. These centers can now perform many structural heart interventions, particularly transcatheter procedures, owing to improvements in procedural safety and device miniaturization. Growing investments, advantageous reimbursement reforms, and patient preference for convenient care settings are all contributing to ASCs' explosive growth and establishing them as a key growth engine in the field of structural heart treatment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by its growing geriatric population, high prevalence of cardiovascular diseases, and sophisticated healthcare infrastructure. In addition to the presence of major market players and established reimbursement policies, the region benefits from large investments in research and development. Additionally, strong market growth is also a result of growing awareness of minimally invasive procedures and the growing use of cutting-edge technologies like transcatheter aortic valve replacement (TAVR) and left atrial appendage closure.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Numerous factors, such as an aging population, easier access to healthcare, and growing awareness of cardiovascular diseases, are responsible for this rapid expansion. India is leading the way in the market for structural heart devices. Furthermore, driving market expansion in the area is the use of minimally invasive procedures like Left Atrial Appendage Closure (LAAC) and Transcatheter Aortic Valve Replacement (TAVR).

Key players in the market

Some of the key players in Structural Heart Devices Market include Boston Scientific Corporation, Artivion, Inc., Medtronic Plc, Edwards Lifesciences Corporation, Abbott Laboratories, JenaValve Technology, Inc., LivaNova PLC, Meril Lifesciences Pvt. Ltd, LifeTech Scientific Corporation, Terumo Corporation, Numed Inc, Atricure, Inc, Cook Group Incorporated, Lepu Medical Inc and Braile Biomedica Inc.

Key Developments:

In May 2025, Artivion, Inc announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025. Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning.

In April 2025, Medtronic plc announced a strategic agreement to distribute the advanced Dragonfly(TM)* pancreaticobiliary system from Dragonfly Endoscopy, Inc. in the United States. This innovative platform introduces significant enhancements in pancreaticobiliary endoscopy - a field where procedural standards have remained largely unchanged for decades. Financial terms of the agreement were not disclosed.

In March 2025, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS(TM) Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

Products Covered:

• Heart Valve Devices
• Annuloplasty Rings
• Occluders and Delivery Systems
• Accessories

Procedures Covered:

• Replacement Procedure
• Repair Procedure

Age Groups Covered:

• Pediatric
• Adults

Indications Covered:

• Atrial Septal Defect (ASD)
• Ventricular Septal Defect (VSD)
• Patent Foramen Ovale (PFO)
• Aortic Valve Stenosis
• Other Indications

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Labs
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Structural Heart Devices Market, By Product

• 5.1 Introduction
• 5.2 Heart Valve Devices
  • 5.2.1 Surgical Heart Valves
  • 5.2.2 Transcatheter Heart Valves
• 5.3 Annuloplasty Rings
• 5.4 Occluders and Delivery Systems
• 5.5 Accessories

6 Global Structural Heart Devices Market, By Procedure

• 6.1 Introduction
• 6.2 Replacement Procedure
  • 6.2.1 Surgical Aortic Valve Replacement (SAVR)
  • 6.2.2 Transcatheter Aortic Valve Replacement (TAVR)
  • 6.2.3 Transcatheter Mitral Valve Replacement (TMVR)
  • 6.2.4 Other Replacement Procedures
• 6.3 Repair Procedure
  • 6.3.1 Left Atrial Appendage Closure (LAAC)
  • 6.3.2 Transcatheter Mitral Valve Repair (TMVr)
  • 6.3.3 Transcatheter Tricuspid Valve Repair (TTVr)
  • 6.3.4 Valvuloplasty
  • 6.3.5 Other Repair Procedures

7 Global Structural Heart Devices Market, By Age Group

• 7.1 Introduction
• 7.2 Pediatric
• 7.3 Adults

8 Global Structural Heart Devices Market, By Indication

• 8.1 Introduction
• 8.2 Atrial Septal Defect (ASD)
• 8.3 Ventricular Septal Defect (VSD)
• 8.4 Patent Foramen Ovale (PFO)
• 8.5 Aortic Valve Stenosis
• 8.6 Other Indications

9 Global Structural Heart Devices Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Ambulatory Surgical Centers
• 9.4 Cardiac Catheterization Labs
• 9.5 Other End Users

10 Global Structural Heart Devices Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Boston Scientific Corporation
• 12.2 Artivion, Inc.
• 12.3 Medtronic Plc
• 12.4 Edwards Lifesciences Corporation
• 12.5 Abbott Laboratories
• 12.6 JenaValve Technology, Inc.
• 12.7 LivaNova PLC
• 12.8 Meril Lifesciences Pvt. Ltd
• 12.9 LifeTech Scientific Corporation
• 12.10 Terumo Corporation
• 12.11 Numed Inc
• 12.12 Atricure, Inc
• 12.13 Cook Group Incorporated
• 12.14 Lepu Medical Inc
• 12.15 Braile Biomedica Inc